# US 12,006,368 B2 · Anti-frizzled antibodies and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,368 B2
- Document ID: US12006368B2
- Status: Granted
- Kind: B2
- Application number: 16/954,482
- Filed: 2018-12-19
- Published: 2021-03-25
- Granted: 2024-06-11
- Earliest claimed: 2017-12-19
- Assignees: Surrozen Operating, Inc.
- Applicants: Surrozen Operating, Inc.
- Inventors: Yang Li; Tom Zhiye Yuan; Aaron Ken Sato; Wen-Chen Yeh; Chenggang Lu; Parthasarathy Sampathkumar; Claudia Yvonne Janda
- Web page: https://patentgrep.com/patent/US12006368B2

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 2299/00: Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

## Claims

### Claim 1

An isolated antibody, or an antigen-binding fragment thereof, that binds to Frizzled 5 and Frizzled 8, comprising:
a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3 sequences set forth as SEQ ID NOs: 218, 410, and 861, respectively; and
a light chain variable region comprising CDRL1, CDRL2 and CDRL3 sequences set forth as SEQ ID NOs: 996, 1071, and 1264, respectively.

### Claim 2 (depends on 1)

The isolated antibody, or antigen-binding fragment thereof, of claim 1, comprising a heavy chain variable region comprising an amino acid sequence having at least 90% identity to the amino acid sequence set forth in SEQ ID NO:7 and a light chain variable region comprising an amino acid sequence having at least 90% identity to the amino acid sequence set forth in SEQ ID NO:44.

### Claim 3 (depends on 1)

The isolated antibody, or antigen-binding fragment thereof, of claim 1, wherein the antibody, or antigen-binding fragment thereof, is humanized.

### Claim 4 (depends on 1)

The isolated antibody, or antigen-binding fragment thereof, of claim 1, wherein the antibody, or antigen-binding fragment thereof, is an IgG antibody, a single chain antibody, a scFv, a univalent antibody lacking a hinge region, a Fab or a Fab′ fragment, or a minibody.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising a physiologically acceptable excipient, diluent, or carrier, and the isolated antibody, or antigen-binding fragment thereof, according to claim 1.

### Claim 6 (depends on 1)

The isolated antibody, or antigen-binding fragment thereof, of claim 1, comprising a heavy chain variable region comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO:7 and a light chain variable region comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO:44.

### Claim 7 (depends on 1)

The isolated antibody, or antigen-binding fragment thereof, of claim 1, comprising a heavy chain variable region comprising an amino acid sequence having at least 98% identity to the amino acid sequence set forth in SEQ ID NO:7 and a light chain variable region comprising an amino acid sequence having at least 98% identity to the amino acid sequence set forth in SEQ ID NO:44.

### Claim 8 (depends on 7)

A pharmaceutical composition comprising a physiologically acceptable excipient, diluent, or carrier, and the isolated antibody, or antigen-binding fragment thereof, according to claim 7.